View Featured Offers >>
8928
Human Interleukin-17A (hIL-17A)
Cytokines & Growth Factors
Growth Factors and Cytokines

Human Interleukin-17A (hIL-17A) #8928

Citations (2)
Western blot analysis of extracts from human foreskin fibroblasts untreated or treated with hIL-17A for 15 minutes, using Phospho-p38 MAPK (Thr180/Tyr182) (3D7) Rabbit mAb #9215 (upper) and p38 MAPK Antibody #9212 (lower).
The production of IL-6 by primary human fibroblasts cultured with increasing concentrations of human IL-17A was assessed. Media from cells incubated with IL-17A for 48 hours was collected and assayed for IL-6 by ELISA and the OD450 - OD650 was determined.
The purity of recombinant hIL-17A was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-17A and staining overnight with Coomassie Blue.

Product Usage Information

¶Reconstitution:¶ ¶With carrier: Add sterile PBS or PBS containing 1% bovine or human serum albumin or 5-10% FBS to a final hIL-17A concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.¶ ¶Carrier free: Add sterile PBS or PBS containing protein to minimize absorption of hIL-17A to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock hIL-17A should be greater than 50 μg/ml.

Storage

Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Product Description

MW (kDa) 21
Purity >97% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-17A. All lots are greater than 97% pure
Endotoxin Less than 0.01 ng endotoxin/1 μg hIL-17A.
Activity The bioactivity of recombinant hIL-17A was determined by its ability to induce IL-6 production by primary human fibroblasts. The ED50 of each lot is between 1.5 - 3.5 ng/ml.
Molecular Formula Recombinant hIL-17A contains no "tags" and the nonglycosylated protein has a calculated MW of 15,535. DTT-reduced protein migrates as a 16-24 kDa polypeptide. Heterogeneity in SDS PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 28-37 kDa protein. The expected amino-terminal IVKAG of recombinant hIL-17A was verified by amino acid sequencing.

Source / Purification

Recombinant human IL-17A (hIL-17A) Ile20-Ala155 (Accession #NP_002181) was expressed in human 293 cells at Cell Signaling Technology.

Background

IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4, 6). Phosphorylation of some Jaks and Stats has been observed.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not for Use in Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.
To Purchase # 8928
Cat. # Size Qty. Price
8928SC
10 µg  (With Carrier)
8928SF
10 µg  (Carrier Free)